Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.50 |
| ▸ | GHSR | Q92847 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698687 | 1.00 | LOXL2 (0.57) | LOXL2SIRT1GHSRSMN1; SMN2CTSV | |
| SCHEMBL287170 | 0.88 | ALOX15 (0.51) | LOXL2GHSRCTSVCTSLGPR84 | |
| SCHEMBL3694098 | 0.82 | LOXL2 (0.54) | LOXL2SIRT1SMN1; SMN2PYGLF7 | |
| SCHEMBL28285787 | 0.81 | GHSR (0.48) | GHSRCTSVCTSLGPR84 | |
| SCHEMBL1461108 | 0.81 | GHSR (0.47) | GHSRCTSVCTSLGPR84 | |
| SCHEMBL2056276 | 0.80 | LOXL2 (0.68) | LOXL2SIRT1SMN1; SMN2F7F3 | |
| SCHEMBL10593440 | 0.80 | SIRT1 (0.56) | LOXL2SIRT1SMN1; SMN2F7F3 | |
| SCHEMBL866136 | 0.79 | LOXL2 (0.72) | LOXL2SIRT1SMN1; SMN2PYGLF7 | |
| SCHEMBL9278047 | 0.79 | GPR84 (0.50) | GHSRCTSVCTSLGPR84 | |
| SCHEMBL1459106 | 0.79 | GHSR (0.46) | LOXL2GHSRCTSVCTSLGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464048-B2 | 5-oxo-ETE receptor antagonist compounds | FLORIDA INSTITUTE OF TECHNOLOGY (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-10-30 | — | — | US | disclosed |
| EP-2427430-B1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | UNIV MCGILL (CA) | 2014-09-10 | — | — | EP | disclosed |
| US-8809382-B2 | 5-oxo-ETE receptor antagonist compounds | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-08-19 | — | — | US | disclosed |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | FLORIDA INSTITUTE OF TECHNOLOGY | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | LOXL2 120/4885SIRT1 3590/4885GHSR 1072/4885 |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | LOXL2 120/4885SIRT1 3590/4885GHSR 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.